調査レポート | • レポートコード：QYR2104Z4490 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、132ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品、ヘルスケア |
| Single User | ￥553,800 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥830,700 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,107,600 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、PEG化薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（高分子薬、小分子薬、ナノ粒子）、用途別市場規模（がん、C型肝炎、白血病、重症複合免疫不全症、関節リウマチ、クローン病、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・PEG化薬の市場動向 ・企業の競争状況、市場シェア ・PEG化薬の種類別市場規模（高分子薬、小分子薬、ナノ粒子） ・PEG化薬の用途別市場規模（がん、C型肝炎、白血病、重症複合免疫不全症、関節リウマチ、クローン病、その他） ・PEG化薬の北米市場規模2016-2027（アメリカ、カナダ） ・PEG化薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・PEG化薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・PEG化薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・PEG化薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AstraZeneca、Bayer Healthcare、Biogen、BioMarin Pharmaceutical Inc、Coherus BioSciences、Enzon、Horizon Therapeutics、Leadiant Biosciences, Inc.、Merck、Mylan、Novo Nordisk、Pfizer、Roche、Sandoz、Servier Pharmaceuticals LLC、Takeda Pharmaceutical Company Limited） ・結論 |
Market Analysis and Insights: Global PEGylated Drugs Market
The global PEGylated Drugs market size is projected to reach US$ 8536.5 million by 2026, from US$ 7003.6 million in 2019, at a CAGR of 2.8% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global PEGylated Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global PEGylated Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global PEGylated Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global PEGylated Drugs market.
Global PEGylated Drugs Scope and Market Size
PEGylated Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global PEGylated Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Macromolecular Drugs
Small Molecular Drugs
Nanoparticles
Segment by Application
Cancer
Hepatitis C
Leukemia
Severe Combined Immunodeficiency Disease
Rheumatoid Arthritis
Crohn Disease
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
AstraZeneca
Bayer Healthcare
Biogen
BioMarin Pharmaceutical Inc
Coherus BioSciences
Enzon
Horizon Therapeutics
Leadiant Biosciences, Inc.
Merck
BioMarin Pharmaceutical Inc
Coherus BioSciences
Pfizer
Roche
Sandoz
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global PEGylated Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Macromolecular Drugs
1.2.3 Small Molecular Drugs
1.2.4 Nanoparticles
1.3 Market by Application
1.3.1 Global PEGylated Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Cancer
1.3.3 Hepatitis C
1.3.4 Leukemia
1.3.5 Severe Combined Immunodeficiency Disease
1.3.6 Rheumatoid Arthritis
1.3.7 Crohn Disease
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global PEGylated Drugs Market Perspective (2016-2027)
2.2 PEGylated Drugs Growth Trends by Regions
2.2.1 PEGylated Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 PEGylated Drugs Historic Market Share by Regions (2016-2021)
2.2.3 PEGylated Drugs Forecasted Market Size by Regions (2022-2027)
2.3 PEGylated Drugs Industry Dynamic
2.3.1 PEGylated Drugs Market Trends
2.3.2 PEGylated Drugs Market Drivers
2.3.3 PEGylated Drugs Market Challenges
2.3.4 PEGylated Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top PEGylated Drugs Players by Revenue
3.1.1 Global Top PEGylated Drugs Players by Revenue (2016-2021)
3.1.2 Global PEGylated Drugs Revenue Market Share by Players (2016-2021)
3.2 Global PEGylated Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by PEGylated Drugs Revenue
3.4 Global PEGylated Drugs Market Concentration Ratio
3.4.1 Global PEGylated Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by PEGylated Drugs Revenue in 2020
3.5 PEGylated Drugs Key Players Head office and Area Served
3.6 Key Players PEGylated Drugs Product Solution and Service
3.7 Date of Enter into PEGylated Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 PEGylated Drugs Breakdown Data by Type
4.1 Global PEGylated Drugs Historic Market Size by Type (2016-2021)
4.2 Global PEGylated Drugs Forecasted Market Size by Type (2022-2027)
5 PEGylated Drugs Breakdown Data by Application
5.1 Global PEGylated Drugs Historic Market Size by Application (2016-2021)
5.2 Global PEGylated Drugs Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America PEGylated Drugs Market Size (2016-2027)
6.2 North America PEGylated Drugs Market Size by Type
6.2.1 North America PEGylated Drugs Market Size by Type (2016-2021)
6.2.2 North America PEGylated Drugs Market Size by Type (2022-2027)
6.2.3 North America PEGylated Drugs Market Size by Type (2016-2027)
6.3 North America PEGylated Drugs Market Size by Application
6.3.1 North America PEGylated Drugs Market Size by Application (2016-2021)
6.3.2 North America PEGylated Drugs Market Size by Application (2022-2027)
6.3.3 North America PEGylated Drugs Market Size by Application (2016-2027)
6.4 North America PEGylated Drugs Market Size by Country
6.4.1 North America PEGylated Drugs Market Size by Country (2016-2021)
6.4.2 North America PEGylated Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe PEGylated Drugs Market Size (2016-2027)
7.2 Europe PEGylated Drugs Market Size by Type
7.2.1 Europe PEGylated Drugs Market Size by Type (2016-2021)
7.2.2 Europe PEGylated Drugs Market Size by Type (2022-2027)
7.2.3 Europe PEGylated Drugs Market Size by Type (2016-2027)
7.3 Europe PEGylated Drugs Market Size by Application
7.3.1 Europe PEGylated Drugs Market Size by Application (2016-2021)
7.3.2 Europe PEGylated Drugs Market Size by Application (2022-2027)
7.3.3 Europe PEGylated Drugs Market Size by Application (2016-2027)
7.4 Europe PEGylated Drugs Market Size by Country
7.4.1 Europe PEGylated Drugs Market Size by Country (2016-2021)
7.4.2 Europe PEGylated Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific PEGylated Drugs Market Size (2016-2027)
8.2 Asia-Pacific PEGylated Drugs Market Size by Type
8.2.1 Asia-Pacific PEGylated Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific PEGylated Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific PEGylated Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific PEGylated Drugs Market Size by Application
8.3.1 Asia-Pacific PEGylated Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific PEGylated Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific PEGylated Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific PEGylated Drugs Market Size by Region
8.4.1 Asia-Pacific PEGylated Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific PEGylated Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America PEGylated Drugs Market Size (2016-2027)
9.2 Latin America PEGylated Drugs Market Size by Type
9.2.1 Latin America PEGylated Drugs Market Size by Type (2016-2021)
9.2.2 Latin America PEGylated Drugs Market Size by Type (2022-2027)
9.2.3 Latin America PEGylated Drugs Market Size by Type (2016-2027)
9.3 Latin America PEGylated Drugs Market Size by Application
9.3.1 Latin America PEGylated Drugs Market Size by Application (2016-2021)
9.3.2 Latin America PEGylated Drugs Market Size by Application (2022-2027)
9.3.3 Latin America PEGylated Drugs Market Size by Application (2016-2027)
9.4 Latin America PEGylated Drugs Market Size by Country
9.4.1 Latin America PEGylated Drugs Market Size by Country (2016-2021)
9.4.2 Latin America PEGylated Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa PEGylated Drugs Market Size (2016-2027)
10.2 Middle East & Africa PEGylated Drugs Market Size by Type
10.2.1 Middle East & Africa PEGylated Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa PEGylated Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa PEGylated Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa PEGylated Drugs Market Size by Application
10.3.1 Middle East & Africa PEGylated Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa PEGylated Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa PEGylated Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa PEGylated Drugs Market Size by Country
10.4.1 Middle East & Africa PEGylated Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa PEGylated Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca PEGylated Drugs Introduction
11.1.4 AstraZeneca Revenue in PEGylated Drugs Business (2016-2021)
11.1.5 AstraZeneca Recent Development
11.2 Bayer Healthcare
11.2.1 Bayer Healthcare Company Details
11.2.2 Bayer Healthcare Business Overview
11.2.3 Bayer Healthcare PEGylated Drugs Introduction
11.2.4 Bayer Healthcare Revenue in PEGylated Drugs Business (2016-2021)
11.2.5 Bayer Healthcare Recent Development
11.3 Biogen
11.3.1 Biogen Company Details
11.3.2 Biogen Business Overview
11.3.3 Biogen PEGylated Drugs Introduction
11.3.4 Biogen Revenue in PEGylated Drugs Business (2016-2021)
11.3.5 Biogen Recent Development
11.4 BioMarin Pharmaceutical Inc
11.4.1 BioMarin Pharmaceutical Inc Company Details
11.4.2 BioMarin Pharmaceutical Inc Business Overview
11.4.3 BioMarin Pharmaceutical Inc PEGylated Drugs Introduction
11.4.4 BioMarin Pharmaceutical Inc Revenue in PEGylated Drugs Business (2016-2021)
11.4.5 BioMarin Pharmaceutical Inc Recent Development
11.5 Coherus BioSciences
11.5.1 Coherus BioSciences Company Details
11.5.2 Coherus BioSciences Business Overview
11.5.3 Coherus BioSciences PEGylated Drugs Introduction
11.5.4 Coherus BioSciences Revenue in PEGylated Drugs Business (2016-2021)
11.5.5 Coherus BioSciences Recent Development
11.6 Enzon
11.6.1 Enzon Company Details
11.6.2 Enzon Business Overview
11.6.3 Enzon PEGylated Drugs Introduction
11.6.4 Enzon Revenue in PEGylated Drugs Business (2016-2021)
11.6.5 Enzon Recent Development
11.7 Horizon Therapeutics
11.7.1 Horizon Therapeutics Company Details
11.7.2 Horizon Therapeutics Business Overview
11.7.3 Horizon Therapeutics PEGylated Drugs Introduction
11.7.4 Horizon Therapeutics Revenue in PEGylated Drugs Business (2016-2021)
11.7.5 Horizon Therapeutics Recent Development
11.8 Leadiant Biosciences, Inc.
11.8.1 Leadiant Biosciences, Inc. Company Details
11.8.2 Leadiant Biosciences, Inc. Business Overview
11.8.3 Leadiant Biosciences, Inc. PEGylated Drugs Introduction
11.8.4 Leadiant Biosciences, Inc. Revenue in PEGylated Drugs Business (2016-2021)
11.8.5 Leadiant Biosciences, Inc. Recent Development
11.9 Merck
11.9.1 Merck Company Details
11.9.2 Merck Business Overview
11.9.3 Merck PEGylated Drugs Introduction
11.9.4 Merck Revenue in PEGylated Drugs Business (2016-2021)
11.9.5 Merck Recent Development
11.10 Mylan
11.10.1 Mylan Company Details
11.10.2 Mylan Business Overview
11.10.3 Mylan PEGylated Drugs Introduction
11.10.4 Mylan Revenue in PEGylated Drugs Business (2016-2021)
11.10.5 Mylan Recent Development
11.11 Novo Nordisk
11.11.1 Novo Nordisk Company Details
11.11.2 Novo Nordisk Business Overview
11.11.3 Novo Nordisk PEGylated Drugs Introduction
11.11.4 Novo Nordisk Revenue in PEGylated Drugs Business (2016-2021)
11.11.5 Novo Nordisk Recent Development
11.12 Pfizer
11.12.1 Pfizer Company Details
11.12.2 Pfizer Business Overview
11.12.3 Pfizer PEGylated Drugs Introduction
11.12.4 Pfizer Revenue in PEGylated Drugs Business (2016-2021)
11.12.5 Pfizer Recent Development
11.13 Roche
11.13.1 Roche Company Details
11.13.2 Roche Business Overview
11.13.3 Roche PEGylated Drugs Introduction
11.13.4 Roche Revenue in PEGylated Drugs Business (2016-2021)
11.13.5 Roche Recent Development
11.14 Sandoz
11.14.1 Sandoz Company Details
11.14.2 Sandoz Business Overview
11.14.3 Sandoz PEGylated Drugs Introduction
11.14.4 Sandoz Revenue in PEGylated Drugs Business (2016-2021)
11.14.5 Sandoz Recent Development
11.15 Servier Pharmaceuticals LLC
11.15.1 Servier Pharmaceuticals LLC Company Details
11.15.2 Servier Pharmaceuticals LLC Business Overview
11.15.3 Servier Pharmaceuticals LLC PEGylated Drugs Introduction
11.15.4 Servier Pharmaceuticals LLC Revenue in PEGylated Drugs Business (2016-2021)
11.15.5 Servier Pharmaceuticals LLC Recent Development
11.16 Takeda Pharmaceutical Company Limited
11.16.1 Takeda Pharmaceutical Company Limited Company Details
11.16.2 Takeda Pharmaceutical Company Limited Business Overview
11.16.3 Takeda Pharmaceutical Company Limited PEGylated Drugs Introduction
11.16.4 Takeda Pharmaceutical Company Limited Revenue in PEGylated Drugs Business (2016-2021)
11.16.5 Takeda Pharmaceutical Company Limited Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global PEGylated Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Macromolecular Drugs
Table 3. Key Players of Small Molecular Drugs
Table 4. Key Players of Nanoparticles
Table 5. Global PEGylated Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global PEGylated Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global PEGylated Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global PEGylated Drugs Market Share by Regions (2016-2021)
Table 9. Global PEGylated Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global PEGylated Drugs Market Share by Regions (2022-2027)
Table 11. PEGylated Drugs Market Trends
Table 12. PEGylated Drugs Market Drivers
Table 13. PEGylated Drugs Market Challenges
Table 14. PEGylated Drugs Market Restraints
Table 15. Global PEGylated Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global PEGylated Drugs Market Share by Players (2016-2021)
Table 17. Global Top PEGylated Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PEGylated Drugs as of 2020)
Table 18. Ranking of Global Top PEGylated Drugs Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by PEGylated Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players PEGylated Drugs Product Solution and Service
Table 22. Date of Enter into PEGylated Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global PEGylated Drugs Market Size by Type (2016-2021) (US$ Million)
Table 25. Global PEGylated Drugs Revenue Market Share by Type (2016-2021)
Table 26. Global PEGylated Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global PEGylated Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global PEGylated Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global PEGylated Drugs Revenue Market Share by Application (2016-2021)
Table 30. Global PEGylated Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global PEGylated Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America PEGylated Drugs Market Size by Type (2016-2021) (US$ Million)
Table 33. North America PEGylated Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America PEGylated Drugs Market Size by Application (2016-2021) (US$ Million)
Table 35. North America PEGylated Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America PEGylated Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America PEGylated Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe PEGylated Drugs Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe PEGylated Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe PEGylated Drugs Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe PEGylated Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe PEGylated Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe PEGylated Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific PEGylated Drugs Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific PEGylated Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific PEGylated Drugs Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific PEGylated Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific PEGylated Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific PEGylated Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America PEGylated Drugs Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America PEGylated Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America PEGylated Drugs Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America PEGylated Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America PEGylated Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America PEGylated Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa PEGylated Drugs Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa PEGylated Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa PEGylated Drugs Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa PEGylated Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa PEGylated Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa PEGylated Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 62. AstraZeneca Company Details
Table 63. AstraZeneca Business Overview
Table 64. AstraZeneca PEGylated Drugs Product
Table 65. AstraZeneca Revenue in PEGylated Drugs Business (2016-2021) & (US$ Million)
Table 66. AstraZeneca Recent Development
Table 67. Bayer Healthcare Company Details
Table 68. Bayer Healthcare Business Overview
Table 69. Bayer Healthcare PEGylated Drugs Product
Table 70. Bayer Healthcare Revenue in PEGylated Drugs Business (2016-2021) & (US$ Million)
Table 71. Bayer Healthcare Recent Development
Table 72. Biogen Company Details
Table 73. Biogen Business Overview
Table 74. Biogen PEGylated Drugs Product
Table 75. Biogen Revenue in PEGylated Drugs Business (2016-2021) & (US$ Million)
Table 76. Biogen Recent Development
Table 77. BioMarin Pharmaceutical Inc Company Details
Table 78. BioMarin Pharmaceutical Inc Business Overview
Table 79. BioMarin Pharmaceutical Inc PEGylated Drugs Product
Table 80. BioMarin Pharmaceutical Inc Revenue in PEGylated Drugs Business (2016-2021) & (US$ Million)
Table 81. BioMarin Pharmaceutical Inc Recent Development
Table 82. Coherus BioSciences Company Details
Table 83. Coherus BioSciences Business Overview
Table 84. Coherus BioSciences PEGylated Drugs Product
Table 85. Coherus BioSciences Revenue in PEGylated Drugs Business (2016-2021) & (US$ Million)
Table 86. Coherus BioSciences Recent Development
Table 87. Enzon Company Details
Table 88. Enzon Business Overview
Table 89. Enzon PEGylated Drugs Product
Table 90. Enzon Revenue in PEGylated Drugs Business (2016-2021) & (US$ Million)
Table 91. Enzon Recent Development
Table 92. Horizon Therapeutics Company Details
Table 93. Horizon Therapeutics Business Overview
Table 94. Horizon Therapeutics PEGylated Drugs Product
Table 95. Horizon Therapeutics Revenue in PEGylated Drugs Business (2016-2021) & (US$ Million)
Table 96. Horizon Therapeutics Recent Development
Table 97. Leadiant Biosciences, Inc. Company Details
Table 98. Leadiant Biosciences, Inc. Business Overview
Table 99. Leadiant Biosciences, Inc. Revenue in PEGylated Drugs Business (2016-2021) & (US$ Million)
Table 100. Leadiant Biosciences, Inc. Recent Development
Table 101. Merck Company Details
Table 102. Merck Business Overview
Table 103. Merck PEGylated Drugs Product
Table 104. Merck Revenue in PEGylated Drugs Business (2016-2021) & (US$ Million)
Table 105. Merck Recent Development
Table 106. Mylan Company Details
Table 107. Mylan Business Overview
Table 108. Mylan PEGylated Drugs Product
Table 109. Mylan Revenue in PEGylated Drugs Business (2016-2021) & (US$ Million)
Table 110. Mylan Recent Development
Table 111. Novo Nordisk Company Details
Table 112. Novo Nordisk Business Overview
Table 113. Novo Nordisk PEGylated Drugs Product
Table 114. Novo Nordisk Revenue in PEGylated Drugs Business (2016-2021) & (US$ Million)
Table 115. Novo Nordisk Recent Development
Table 116. Pfizer Company Details
Table 117. Pfizer Business Overview
Table 118. Pfizer PEGylated Drugs Product
Table 119. Pfizer Revenue in PEGylated Drugs Business (2016-2021) & (US$ Million)
Table 120. Pfizer Recent Development
Table 121. Roche Company Details
Table 122. Roche Business Overview
Table 123. Roche PEGylated Drugs Product
Table 124. Roche Revenue in PEGylated Drugs Business (2016-2021) & (US$ Million)
Table 125. Roche Recent Development
Table 126. Sandoz Company Details
Table 127. Sandoz Business Overview
Table 128. Sandoz PEGylated Drugs Product
Table 129. Sandoz Revenue in PEGylated Drugs Business (2016-2021) & (US$ Million)
Table 130. Sandoz Recent Development
Table 131. Servier Pharmaceuticals LLC Company Details
Table 132. Servier Pharmaceuticals LLC Business Overview
Table 133. Servier Pharmaceuticals LLC PEGylated Drugs Product
Table 134. Servier Pharmaceuticals LLC Revenue in PEGylated Drugs Business (2016-2021) & (US$ Million)
Table 135. Servier Pharmaceuticals LLC Recent Development
Table 136. Takeda Pharmaceutical Company Limited Company Details
Table 137. Takeda Pharmaceutical Company Limited Business Overview
Table 138. Takeda Pharmaceutical Company Limited PEGylated Drugs Product
Table 139. Takeda Pharmaceutical Company Limited Revenue in PEGylated Drugs Business (2016-2021) & (US$ Million)
Table 140. Takeda Pharmaceutical Company Limited Recent Development
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Global PEGylated Drugs Market Share by Type: 2020 VS 2027
Figure 2. Macromolecular Drugs Features
Figure 3. Small Molecular Drugs Features
Figure 4. Nanoparticles Features
Figure 5. Global PEGylated Drugs Market Share by Application: 2020 VS 2027
Figure 6. Cancer Case Studies
Figure 7. Hepatitis C Case Studies
Figure 8. Leukemia Case Studies
Figure 9. Severe Combined Immunodeficiency Disease Case Studies
Figure 10. Rheumatoid Arthritis Case Studies
Figure 11. Crohn Disease Case Studies
Figure 12. Others Case Studies
Figure 13. PEGylated Drugs Report Years Considered
Figure 14. Global PEGylated Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global PEGylated Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global PEGylated Drugs Market Share by Regions: 2020 VS 2027
Figure 17. Global PEGylated Drugs Market Share by Regions (2022-2027)
Figure 18. Global PEGylated Drugs Market Share by Players in 2020
Figure 19. Global Top PEGylated Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PEGylated Drugs as of 2020
Figure 20. The Top 10 and 5 Players Market Share by PEGylated Drugs Revenue in 2020
Figure 21. Global PEGylated Drugs Revenue Market Share by Type (2016-2021)
Figure 22. Global PEGylated Drugs Revenue Market Share by Type (2022-2027)
Figure 23. North America PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America PEGylated Drugs Market Share by Type (2016-2027)
Figure 25. North America PEGylated Drugs Market Share by Application (2016-2027)
Figure 26. North America PEGylated Drugs Market Share by Country (2016-2027)
Figure 27. United States PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe PEGylated Drugs Market Share by Type (2016-2027)
Figure 31. Europe PEGylated Drugs Market Share by Application (2016-2027)
Figure 32. Europe PEGylated Drugs Market Share by Country (2016-2027)
Figure 33. Germany PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific PEGylated Drugs Market Share by Type (2016-2027)
Figure 41. Asia-Pacific PEGylated Drugs Market Share by Application (2016-2027)
Figure 42. Asia-Pacific PEGylated Drugs Market Share by Region (2016-2027)
Figure 43. China PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America PEGylated Drugs Market Share by Type (2016-2027)
Figure 51. Latin America PEGylated Drugs Market Share by Application (2016-2027)
Figure 52. Latin America PEGylated Drugs Market Share by Country (2016-2027)
Figure 53. Mexico PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa PEGylated Drugs Market Share by Type (2016-2027)
Figure 57. Middle East & Africa PEGylated Drugs Market Share by Application (2016-2027)
Figure 58. Middle East & Africa PEGylated Drugs Market Share by Country (2016-2027)
Figure 59. Turkey PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE PEGylated Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. AstraZeneca Revenue Growth Rate in PEGylated Drugs Business (2016-2021)
Figure 63. Bayer Healthcare Revenue Growth Rate in PEGylated Drugs Business (2016-2021)
Figure 64. Biogen Revenue Growth Rate in PEGylated Drugs Business (2016-2021)
Figure 65. BioMarin Pharmaceutical Inc Revenue Growth Rate in PEGylated Drugs Business (2016-2021)
Figure 66. Coherus BioSciences Revenue Growth Rate in PEGylated Drugs Business (2016-2021)
Figure 67. Enzon Revenue Growth Rate in PEGylated Drugs Business (2016-2021)
Figure 68. Horizon Therapeutics Revenue Growth Rate in PEGylated Drugs Business (2016-2021)
Figure 69. Leadiant Biosciences, Inc. Revenue Growth Rate in PEGylated Drugs Business (2016-2021)
Figure 70. Merck Revenue Growth Rate in PEGylated Drugs Business (2016-2021)
Figure 71. Mylan Revenue Growth Rate in PEGylated Drugs Business (2016-2021)
Figure 72. Novo Nordisk Revenue Growth Rate in PEGylated Drugs Business (2016-2021)
Figure 73. Pfizer Revenue Growth Rate in PEGylated Drugs Business (2016-2021)
Figure 74. Roche Revenue Growth Rate in PEGylated Drugs Business (2016-2021)
Figure 75. Sandoz Revenue Growth Rate in PEGylated Drugs Business (2016-2021)
Figure 76. Servier Pharmaceuticals LLC Revenue Growth Rate in PEGylated Drugs Business (2016-2021)
Figure 77. Takeda Pharmaceutical Company Limited Revenue Growth Rate in PEGylated Drugs Business (2016-2021)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed
世界のPEG化医薬品市場 2021：企業別、地域別、種類・用途別 The PEGylated Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, re…- 世界のクラッベ病治療薬市場規模・現状・予測（2021年-2027年） Krabbe disease is an uncommon and typically deadly concern of the nervous system. It is an acquired hereditary sickness, which implies that it is passed down in families. Individuals with Krabbe disease are not able to make a sufficient substance called galactosylceramidase, which is expected to mak…
- 世界のクラッベ病治療薬市場規模・現状・予測（2021年-2027年） Krabbe disease is an uncommon and typically deadly concern of the nervous system. It is an acquired hereditary sickness, which implies that it is passed down in families. Individuals with Krabbe disease are not able to make a sufficient substance called galactosylceramidase, which is expected to mak…
- 世界のメニエール病治療薬市場規模・現状・予測（2021年-2027年） Meniere’s disease is a disorder of middle ear that causes vertigo, ringing sound in the ear and hearing problems. In most of the cases this disease only affects one ear. Meniere’s disease can affect anyone but the prevalence is on a higher side in people aged from 20-50. This is a chronic disease bu…
- 世界の関節リウマチ（RA）治療薬市場 2021：企業別、地域別、種類・用途別 The Rheumatoid Arthritis (RA) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade…